Treatment with lecanemab is expected to extend independence in IADLs by approximately 10 months, while donanemab may extend independence by about 13 months for patients with a baseline CDR-SB of 2.
The study demonstrated that the repositioned drugs could modify the expression of complement genes in astrocytes, suggesting potential therapeutic benefits for AD patients. Additionally, the framework established a method for better patient stratification, which may enhance treatment efficacy.
Participants showed significant improvements in global cognition, cognitive processing speed, and walking endurance/aerobic fitness, with high satisfaction reported (90.6%).
Improved sleep could potentially reduce WMH accumulation and slow cognitive decline in older adults with AD and MCI.
Improvement in verbal fluency and response inhibition was observed in the right STN DBS group, while the left STN DBS group experienced a decline in verbal fluency over time.
Reduction of oligomeric tau at synapses may protect against synaptic degeneration and cognitive decline in Alzheimer's disease.
Statistically significant reduction in cognitive and functional decline was observed, with effect sizes of 0.09 on CDR-SB, 0.33 on ADAS-Cog, and 0.13 on MMSE for each 0.1-unit decrease in PET β-amyloid SUVR.
Vaccinated individuals showed a reduced risk of developing dementia, with an adjusted hazard ratio of 0.72, indicating a significant protective effect, particularly against vascular dementia compared to Alzheimer's disease.
Hearing aid users with MCI had a significantly lower risk of developing dementia (hazard ratio 0.73) and experienced a slower rate of cognitive decline compared to non-users.
Participants in the CBSDM group showed increased knowledge of dementia risk factors and improved exercise habits, with moderate to large effect sizes observed for both groups.
Subjects receiving ergothioneine showed improved learning ability and stabilized neurofilament light chain levels, indicating enhanced memory and reduced neuronal damage compared to the placebo group.
Cataracts were associated with a higher hazard of all-cause dementia and vascular dementia, with evidence suggesting that cataract extraction could potentially reduce dementia risk.
Motor task acquisition significantly predicted bilateral hippocampal volume, suggesting its potential as a non-invasive screening tool for identifying AD risk and progression.
The study found a tendency towards decreased dementia risk in individuals exposed to antiherpetic medication, with some cohorts showing significant reductions in dementia incidence compared to untreated individuals with herpes infections.
Reducing soluble p-tau levels may slow the accumulation of tau aggregates and mitigate cognitive decline in early Alzheimer's disease.
The combination therapy resulted in a 44% delay in cognitive decline at 5 years and a 47% delay at 10 years, as measured by MMSE and CDR-SB scores, with females and APOE4 carriers showing the greatest cognitive benefits.
There was little evidence that lipid-regulating agents reduced the risk of Alzheimer's disease, but they were associated with an increased risk of all-cause and vascular dementia.
The study provides evidence of a significant association between the use of these antipsychotics and an increased risk of developing Alzheimer's disease and other dementias.
27.0% of patients on CEIs reported improvement in cognitive symptoms, and 34.8% reported stable symptoms. 69.3% of patients on SSRIs reported improvement in neuropsychiatric symptoms.